Nervgen Pharma (NGEN) Other Non-Current Assets (2024 - 2026)
Nervgen Pharma's (NGEN) quarterly Other Non-Current Assets came in at $87164.5 in Q2 2026, down 70.32% quarter-over-quarter from $293682.1 in Q4 2024.
Powered by 
Analysis
Nervgen Pharma (NGEN) Other Non-Current Assets (2024 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported Other Non-Current Assets for 2 consecutive years, with $87164.5 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $87164.5 in Q2 2026; TTM through Jun 2026 was $87164.5, a N/A change from a year earlier, with the FY2024 full-year figure at $299651.5, changed N/A from the prior year.
- Other Non-Current Assets was $87164.5 for Q2 2026 at Nervgen Pharma, down from $293682.1 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $293682.1 in Q4 2024 and troughed at $87164.5 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.35 Bn | 192.36 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 180.10 Bn | 176.92 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 131.31 Bn | 123.46 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.77 Bn | 73.78 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.56 Bn | 55.38 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 53.68 Bn | 48.54 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.44 Bn | 30.14 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.80 Bn | 30.52 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.12 Bn | 29.12 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Nervgen Pharma | 152.62 Mn | 152.62 Mn | - | 87,164.55 |